The Druley lab awarded RO1


The National Cancer Institute awarded the Druley Lab a 5-year RO1 award to apply Error-Corrected Sequencing (ECS) to study children with de novo¬†acute myeloid leukemia (AML). In collaboration with the Children’s Oncology Group, we will apply¬†ECS to characterize approximately 2,000 samples from children treated in the largest AML study ever performed in North America. Results will not only include a direct comparison to the current gold standard, multiparameter flow cytometry, but also attempt to perform machine learning including age, sex, germline variation and cytogenetic anomalies to significantly enhance risk stratification and prognostication in the deadliest leukemia in children. Look for a new publication on the application of ECS coming out soon in Nature Communications!